In most recent advancements, RNA editing uses the CRISPR-Cas13 system, a newer technique that was created specifically to help develop therapies that work with RNA. DNA editing is permanent, which ...

CRISPR-guided endonucleases were an obvious route, but for RNA, the options were few and imperfect. Cas13 proved useful for RNA knockdown, but it caused collateral damage to non-target RNA. Although ...

We demonstrate that RNA-targeting CRISPR effector Cas13 can be engineered for RNA diagnostics and mammalian cell RNA knockdown, binding, and editing. We demonstrate diagnostic applications of Cas13 ...

Over the years, scientists have explored alternatives to Cas9, such as Cas12a for more precise multigene editing, a type III CRISPR for RNA editing, and a Cas13 loaded with multiple guide RNAs for ...

CRISPR has revolutionized the biosciences over the past decade. The RNA-targeting CRISPR effector protein Cas13, discovered in 2016, opened up a myriad of new applications for CRISPR-based ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Efficient and site-specific genome engineering can be achieved based on programmable nucleic acid cleavage using CRISPR-Cas surveillance complexes. Structure-function studies on single component Cas ...